Additional file 3: Detailed adverse event outcomes in each trial

Study # condition duration	Patients and methods	Dosing regimen, numbers of patients	Withdrawals			Adverse Events							
			All causes	Lack of Efficacy	Adverse event	General	GI-related		GI tolerability	Cardiorenal-related		Laboratory Tests	Treatment-related
Osteoarthritis													
C-002 OA 12 weeks	OA Hip/Knee (ACR), requiring NSAID, and with stable controlled hypertension and Type 2 diabetes FCC 1-3 Washout 7-10 days Double dummy method Assessed at baseline, 6, 12 weeks QS 5/5; VS 16/16	Cele 1x200mg/day (n=136) Rofe 1x25mg/day (n=132) Naprox 2x500mg/day (n=128)	Cele 30/136 Rofe 37/132 Naprox 32/128	Cele 3/136 Rofe 1/132 Naprox 3/128	Cele 6/136 Rofe 13/132 Naprox 10/128 GI-related: Cele 1/136 Rofe 1/132 Naprox 4/128	Any AE: Cele 72/136 Rofe 71/132 Naprox 73/128 GI-related: Cele 25/136 Rofe 28/132 Naprox 32/129 Serious: Cele 4/136 Rofe 5/132 (1 MI, 1 aggravated hypertension) Naprox 3/128 Serious UGI: None	Dyspepsia: Cele 1/136 Rofe 1/132 Naprox 1/128 Abdom Pain: Cele 5/136 Rofe 5/132 Naprox 7/128 Nausea: Cele 4/136 Rofe 7/132 Naprox 8/128 Diarrhoea: Cele 6/136 Rofe 10/132 Naprox 4/128 Vomiting: Cele 1/136 Rofe 2/132 Naprox 1/128	Duodenal Ulcer: Cele 1/136 Rofe 0/132 Naprox 0/128 Gastric erosion: Cele 1/136 Rofe 1/132 Naprox 1/128	Mod/severe abdom pain, nausea, dyspepsia: Cele: 5/136 Rofe 11/132 Naprox 9/128	Clinically significant oedema: Cele 7/136 Rofe 10/132 Naprox 4/128 Elevated systolic BP: Cele10% Rofe 14% Naprox 8% Elevated diastolic BP: Cele 4% Rofe 6% Naprox 4% Heart failure: None reported	From treatment emergent AEs Oedema: Cele 1/136 Rofe 3/132 Naprox 2/128 Facial oedema: Cele 1/136 Rofe 0/132 Naprox 0/128 Ankle oedema: Cele 1/136 Rofe 0/132 Naprox 0/128 Hypertension: Cele 1/136 Rofe 0/132 Naprox 0/128 Aggravated hypertension: Cele 0/136 Rofe 3/132 Naprox 3/128 MI: Cele 0/132 Rofe 1/132 Naprox 0/128	Non-significant decreases in Hb in each group	All AEs: Cele 5/136 Rofe 13/132 Nap 13/128 Serious: Cele 0/136 Rofe 2/132 Naprox 0/128
C-003 OA 6 weeks	OA knee (ACR) with flare, requiring daily NSAID/analgesic FCC 1-3 Washout≥2 days Double dummy method Assessed at baseline, 3, 6 weeks QS 5/5; VS 16/16	Cele 1x200mg/day (n=189) Rofe 1x25mg/day (n=190) Plac (n=96)	Cele 31/189 Rofe 29/190 Plac 34/98	Cele 10/189 Rofe 10/190 Plac 21/96	Cele 11/189 Rofe 10/190 Plac 5/96 GI-related: Cele 5/189 Rofe 3/190 Plac 1/96	Any AE: Cele 82/189 Rofe 80/190 Plac 29/92 GI-related: Cele 31/189 Rofe 24/190 Placebo 9/96 Serious: Cele 3/189 Rofe 1/190 Plac 3/96 Serious UGI: Cele 0/189 Rofe 0/190 Plac 1/96 (GIH)	Dyspepsia: Cele 11/189 Rofe 10/190 Placebo 3/96 Abdom Pain: Cele 3/189 Rofe 2/190 Plac 2/96 Nausea: Cele 1/189 Rofe 3/190 Plac 1/96 Diarrhoea: Cele 8/189 Rofe 5/190 Plac 1/96 Vomiting: Cele 1/189 Rofe 0/190 Plac 0/96	GI Haemorrhage: Cele 0/189 Rofe 0/190 Plac 1/96 No ulcers or erosions	Mod/severe abdom pain, nausea, dyspepsia: Cele 6/189 Rofe 7/190 Plac 2/96	Peripheral oedema: Cele 5/189 Rofe 8/190 Plac 2/96 Generalised oedema: Cele 1/189 Rofe 3/190 Plac 0/96 Hypertension: Cele 1/189 Rofe 6/190 Plac 0/96 Aggravated hypertension: Cele 1/189 Rofe 0/190 Plac 1/96	Trial did not report any cases of heart failure	No patient withdrew due to clinically relevant laboratory values	All AEs: Cele 17/189 Rofe 15/190 Plac 4/96 Serious: Cele 1/189 Rofe 0/190 Plac 0/96
C-010 OA 6 weeks	Symptomatic OA hip/knee, K-L 2-4, requiring NSAID±analgesic Initial pain intensity 40-90 on 100mm VAS Washout 3 days or 5 x half-life No investigational medication >30 days Doble dummy method Assessed at baseline, 6 weeks QS 5/5; VS 16/16	Cele 1x200mg/day (n=181) Para 4x1000mg/day (n=171) Plac (n=172) 1st treatment period analysed	Cele 42/181 Para 42/171 Plac 50/172	[consent withdrawn] Cele 14/181 Para 17/171 Placebo 24/172	Any AE: Cele 11/181 Para 15/171 Plac 12/172 GI-related: Cele 5/181 Para 6/171 Plac 2/172	Any AE: Cele 74/181 Para 75/171 Plac 71/172 GI-related: Cele 33/181 Para 25/171 Plac 19/172 Serious: Cele 0/181 Para 2/171 Plac 3/172 Serious UGI: Cele 0/181 Para 0/171 Plac 1/172	Dyspepsia: Cele 10/181 Para 5/171 Plac 1/172 Nausea: Cele: 8/181 Para: 5/171 Plac 4/172 Diarrhoea: Cele 6/181 Para 14/171 Plac 4/172 Abdom Pain: Cele 1/181 Para 4/171 Plac 3/172 Vomiting: Cele 1/181 Para 4/171 Plac 4/172		Mod/severe abdom pain, nausea, dyspepsia: Cele 6/181 Para 7/171 Plac 2/172	Periph Oedema: Cele 3/181 Para 1/171 Placebo 0/172 Leg Oedema: Cele 1/181 Para 0/171 Placebo 0/172 Aggravated hypertension: Cele 0/181 Para 1/171 Placebo 0/172	Cardiac failure: Trial did not report any cases MI: Trial did not report any cases	Group mean data given Hct values unchanged in period 1. Very small changes in mean Hb values with no sig difference between groups	All AEs: Cele 24/181 Para 22/171 Plac 13/172 No serious AEs were related to the study medication
C-013 OA 2 weeks	OA (ACR) with flare FCC 1-3 Assessment at baseline, 1, 2 weeks Washout 2-14 days Double dummy method QS 5/5; VS 16/16	Cele [1] 2x40mg/day (n=73) Cele [2] 2x100mg/day (n=75) Cele [3] 2x200mg/day (n=73) Plac (n=70)	Cele [1] 9/73 Cele [2] 9/75 Cele [3] 6/73 Plac 15/70	Cele [1] 6/73 Cele [2] 1/75 Cele [3] 3/73 Plac 10/70	Cele [1] 0/73 Cele [2] 5/75 Cele [3] 1/73 Plac 2/70 GI-related: Cele [1] 0/73 Cele [2] 1/75 Cele [3] 0/73 Plac 1/70	Any: Cele [1] 30/73 Cele [2] 35/75 Cele [3] 36/73 Plac 30/70 GI-related: Cele [1] 10/73 Cele [2] 15/75 Cele [3] 14/73 Plac 10/70 Serious: Cele [1] 0/73 Cele [2] 1/75 Cele [3] 1/75 Plac 0/70 Serious UGI: None reported Serious CV: Cele [1] 0/73 Cele [2] 0/75 Cele [3] 1/73 Plac 0/70	Dyspepsia: Cele [1] 2/73 Cele [2] 5/75 Cele [3] 3/73 Plac 7/70 Abdom pain: Cele [1] 2/73 Cele [2] 2/75 Cele [3] 4/73 Plac 1/70 Nausea: Cele [1] 3/73 Cele [2] 5/75 Cele [3] 2/73 Plac 0/70 Diarrhoea: Cele [1] 5/73 Cele [2] 3/75 Cele [3] 6/73 Plac 2/70 No vomiting reported		Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 7/73 Cele [2] 3/75 Cele [3] 5/73 Plac 5/70	Peripheral oedema: Cele [1] 1/73 Cele [2] 1/75 Cele [3] 0/73 Plac 0/70 No report of hypertension, MI or CHF		No clinically important laboratory abnormalities were noted	Cele [1] 3/73 Cele [2] 6/75 Cele [3] 7/73 Plac 2/70 No serious AEs drug-related
C-020 OA 12 weeks	OA Knee/Hip (ACR) with flare FCC 1-3 Assessment at baseline, 2, 6, 12 weeks Washout 2 -4 days Double dummy method QS 5/5; VS 16/16	Cele [1] 2x50mg/day (n=218) Cele [2] 2x100mg/day (n=217) Cele [3] 2x200mg/day (n=222) Naprox 2x500mg/day (n=216) Plac (n=219)	Cele [1] 92/218 Cele [2] 91/217 Cele [3] 79/222 Naprox 85/216 Plac 121/219	Cele [1] 67/218 Cele [2] 44/217 Cele [3] 52/222 Naprox 55/216 Plac 87/219	Cele [1] 19/218 Cele [2] 35/217 Cele [3] 23/222 Naprox 18/216 Plac 17/219 GI-related: Cele [1] 9/218 Cele [2] 12/217 Cele [3] 7/222 Naprox 13/216 Plac 5/219	Any: Cele [1] 150/218 Cele [2] 150/217 Cele [3] 144/222 Naprox 137/216 Plac 130/219 GI-related: Cele [1] 61/218 Cele [2] 58/217 Cele [3] 54/222 Naprox 69/216 Plac 49/219 Serious: Cele [1] 1/218 Cele [2] 5/217 Cele [3] 4/222 Naprox 3/216 Plac 4/219 Serious UGI: Cele [1] 0/218 Cele [2] 0/217 Cele [3] 0/222 Naprox 1/216 (GI Bleed) Plac 2/219 Serious CV: Cele [1] 1/218 Cele [2] 0/217 Cele [3] 3/222 Naprox 0/216 Plac 1/219	Dyspepsia: Cele [1] 24/218 Cele [2] 22/217 Cele [3] 22/222 Naprox 25/216 Plac 18/219 Abdom Pain: Cele [1] 8/218 Cele [2] 8/217 Cele [3] 11/222 Naprox 9/216 Plac 8/219 Nausea: Cele [1] 11/218 Cele [2] 8/217 Cele [3] 7/222 Naprox 14/216 Placebo 14/219 Diarrhoea: Cele [1] 12/218 Cele [2] 11/217 Cele [3] 15/222 Naprox 12/216 Plac 10/219 Vomiting: Cele [1] 2/218 Cele [2] 4/217 Cele [3] 4/222 Naprox 2/216 Placebo 1/219	Duodenal ulcer: Cele [1] 1/218 Cele [2] 0/217 Cele [3] 0/222 Naprox 0/216 Plac 0/219 GIH: Cele [1] 0/218 Cele [2] 0/217 Cele [3] 0/222 Naprox 1/216 Plac 0/219 Gastric ulcer: Cele [1] 0/218 Cele [2] 0/217 Cele [3] 0/222 Naprox 1/216 Plac 0/216	Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 22/218 Cele [2] 16/217 Cele [3] 19/222 Naprox 25/216 Plac 18/219	Generalised Oedema: Cele [1] 1/218 Cele [2] 1/217 Cele [3] 1/222 Naprox 2/216 Placebo 0/219 Peripheral Oedema: Cele [1] 5/218 Cele [2] 4/217 Cele [3] 9/222 Naprox 4/216 Plac 3/219 Facial oedema: Cele [1] 0/218 Cele [2] 3/217 Cele [3] 0/222 Naprox 0/216 Plac 1/219	Hypertension: Cele [1] 1/218 Cele [2] 3/217 Cele [3] 1/222 Naprox 0/216 Plac 2/219 Aggravated Hypertension: Cele [1] 0/218 Cele [2] 2/217 Cele [3] 4/222 Naprox 0/216 Plac 1/219 MI: Cele [1] 0/218 Cele [2] 0/217 Cele [3] 3/222 Naprox 0/216 Plac 0/219 Cardiac Failure: Cele [1] 1/218 Cele [2] 0/217 Cele [3] 0/222 Naprox 0/216 Plac 0/219	Hct ≥5% decrease: Cele [1] 11/218 Cele [2] 13/217 Cele [3] 34/222 Naprox 25/216 Plac 21/219 No other clinically relevant lab results seen in more than 2% of patients in any group	Cele [1] 17/218 Cele [2] 21/217 Cele [3] 17/222 Naprox 15/216 Plac 12/219

C-021 OA 12 weeks	OA Knee/Hip (ACR), with flare FCC 1-3 Assessment at baseline, 2, 6, 12 weeks Endoscopy at baseline, 12 weeks Washout 2-14 days Double dummy method QS 5/5; VS 16/16	Cele [1] 2x50mg/day (n=258) Cele [2] 2x100mg/day (n=239) Cele [3] 2x200mg/day (n=237) Naprox 2x500mg/day (n=233) Plac (n=247)	Cele [1] 86/258 Cele [2] 75/240 Cele [3] 79/237 Naprox 81/233 Plac 127/247	Cele [1] 58/258 Cele [2] 51/239 Cele [3] 49/237 Naprox 41/233 Plac 92/247	Cele [1] 16/258 Cele [2] 16/239 Cele [3] 23/237 Naprox 0/233 Plac 14/247 GI-related: Cele [1] 7/258 Cele [2] 10/239 Cele [3] 8/237 Naprox 18/233 Plac 5/247	Any: Cele [1] 164/258 Cele [2] 157/239 Cele [3] 161/237 Naprox 172/233 Plac 147/247 GI-related: Cele [1] 69/258 Cele [2] 62/239 Cele [3] 74/237 Naprox 93/233 Plac 72/247 Serious: Cele [1] 1/258 Cele [2] 4/239 Cele [3] 7/237 Naprox 7/233 Plac 5/247 Serious UGI: Cele [1] 1/258 Cele [2] 2/239 Cele [3] 1/237 Naprox 1/233 Plac 1/247 Serious CV: Cele [1] 0/258 Cele [2] 1/239 Cele [3] 3/237 Naprox 1/233 Plac 3/247	Dyspepsia: Cele [1] 24/258 Cele [2] 20/239 Cele [3] 29/237 Naprox 39/233 Plac 22/247 Abdom pain: Cele [1] 15/258 Cele [2] 11/239 Cele [3] 14/237 Naprox 18/233 Plac 9/247 Nausea: Cele [1] 7/258 Cele [2] 9/239 Cele [3] 12/237 Naprox 15/233 Plac 14/247 Diarrhoea: Cele [1] 17/258 Cele [2] 13/239 Cele [3] 16/237 Naprox 14/233 Plac 15/247 Vomiting: Cele [1] 3/258 Cele [2] 2/239 Cele [3] 3/237 Naprox 6/233 Plac 2/247	Duodenal ulcer: Cele [1] 0/258 Cele [2] 0/239 Cele [3] 0/237 Naprox 2/233 Plac 0/247 Gastric ulcer: Cele [1] 0/258 Cele [2] 1/239 Cele [3] 0/237 Naprox 3/233 Plac 0/247	Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 13/258 Cele [2] 18/239 Cele [3] 30/237 Naprox 37/233 Plac 22/247	Peripheral oedema: Cele [1] 6/258 Cele [2] 6/239 Cele [3] 7/237 Naprox 5/233 Plac 4/247 Facial oedema: Cele [1] 1/258 Cele [2] 1/239 Cele [3] 1/237 Naprox 1/233 Plac 1/247 Hypertension: Cele [1] 1/258 Cele [2] 1/239 Cele [3] 2/237 Naprox 5/233 Plac 1/247 Aggravated Hypertension: Cele [1] 0/258 Cele [2] 2/239 Cele [3] 0/237 Naprox 2/233 Plac 2/247	Cardiac Failure: Cele [1] 0/258 Cele [2] 0/239 Cele [3] 1/237 Naprox 0/233 Plac 0/247 No report of MI	Hct ≥5% decrease: Cele [1] 22/258 Cele [2] 23/239 Cele [3] 24/237 Naprox 19/233 Plac 17/247 No other medically significant or drug related abnormalities were noted	Cele [1] 23/258 Cele [2] 16/239 Cele [3] 21/237 Naprox 27/233 Plac 14/247
C-042 OA 6 weeks	Symptomatic OA Hip/knee (ACR) at least 6 months, requiring NSAID FCC 1-3 Washout 2-5 days Assessment baseline, 2, 4, 6 weeks Double dummy method QS 5/5; VS 16/16	Cele 200mg/day (n=346) Diclo 100mg/day (n=341)	Cele 31/349 Diclo 40/341	Cele 4/346 Diclo 3/341	Cele 22/346 Diclo 29/341 GI-related: Cele 8/346 Diclo 16/341	Any: Cele 150/346 Diclo 180/341 GI related: Cele 59/346 Diclo 90/341 Serious: Cele 3/346 Diclo 4/341 Serious UGI: None Serious CV: Cele 1/346 Diclo 1/341	Dyspepsia: Cele 11/346 Diclo 23/341 Abdom pain: Cele 17/346 Diclo 23/341 Nausea: Cele 11/346 Diclo 17/341 Diarrhoea: Cele 22/346 Diclo 26/341 Vomiting: Cele 4/346 Diclo 3/341		Mod/severe abdom pain, nausea, dyspepsia: Cele 11/346 Diclo 30/341	Generalised oedema: Cele 1/346 Diclo 0/341 Peripheral oedema: Cele 7/346 Diclo 8/341 Hypertension: Cele 3/346 Diclo 0/341 Aggravated Hypertension: Cele 0/346 Diclo 4/341 No report of MI or CHF		No clinically important laboratory abnormalities were noted	Cele 47/346 Diclo 62/341 5 serious AEs not drug-related
C-047 OA 4 weeks	OA Knee (ACR) with flare FCC 1-3 Washout NSAID 2 days, other 5 half-lives Assessment at baseline, 2, 4 weeks QS 5/5; VS 16/16	Cele [1] 50mg/day (n=100) Cele [2] 200mg/day (n=101) Cele [3] 800mg/day (n=99) Plac (n=101)	Cele [1] 24/100 Cele [2] 22/101 Cele [3] 23/99 Plac 31/101	Cele [1] 15/100 Cele [2] 13/101 Cele [3] 10/99 Plac 23/101	Cele [1] 5/100 Cele [2] 4/101 Cele [3] 10/99 Plac 5/101 GI-related: Cele [1] 0/100 Cele [2] 1/101 Cele [3] 2/99 Plac 0/101	Any: Cele [1] 61/100 Cele [2] 59/101 Cele [3] 56/99 Plac 56/101 GI-related: Cele [1] 24/100 Cele [2] 23/101 Cele [3]16/99 Plac 9/101 Serious: Cele [1] 1/100 Cele [2] 2/101 Cele [3] 1/99 Plac 1/101 Serious UGI: Cele [1] 1/100 Cele [2] 0/101 Cele [3] 0/99 Plac 0/101 Serious CV: Cele [2] 1/101 Remaining =0	Dyspepsia: Cele [1] 9/100 Cele [2] 9/101 Cele [3] 10/99 Plac 1/101 Abdom pain: Cele [1] 1/100 Cele [2] 0/101 Cele [3] 3/99 Plac 1/101 Nausea: Cele [1] 0/100 Cele [2] 5/101 Cele [3] 0/99 Plac 0/101 Diarrhoea: Cele [1] 10/100 Cele [2] 5/101 Cele [3] 3/99 Plac 2/101 Vomiting: Cele [1] 0/100 Cele [2] 1/101 Cele [3] 2/99 Plac 0/101		Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 3/100 Cele [2] 7/101 Cele [3] 4/99 Plac 1/101	Peripheral Oedema: Cele [1] 2/100 Cele [2] 1/101 Cele [3] 2/99 Plac 3/101 Aggravated hypertension: Cele [1] 0/100 Cele [2] 0/101 Cele [3] 2/99 Plac 0/101 No report of MI or CHF		No clinically important laboratory abnormalities were noted	Cele [1] 1/100 Cele [2] 4/101 Cele [3] 12/99 Plac 3/101
C-054 OA 12 weeks	OA Hip (ACR) with flare FCC 1-3 Washout 2-4 days Assessment at baseline, 2, 6, 12 weeks Double dummy method QS 5/5; VS16/16	Cele [1] 100mg/day (n=216) Cele [2] 200mg/day (n=207) Cele [3] 400mg/day (n=213) Naprox 1000mg/day (n=207) Plac (n=217)	Cele [1] 105/216 Cele [2] 96/207 Cele [3] 94/213 Naprox 89/207 Plac 138/217	Cele [1] 76/216 Cele [2] 61/207 Cele [3] 55/213 Naprox 51/207 Plac 113/217	Cele [1] 17/216 Cele [2] 27/207 Cele [3] 25/213 Naprox 29/207 Plac 16/217 GI-related: Cele [1] 6/216 Cele [2] 7/207 Cele [3] 11/213 Naprox 17/207 Plac 6/217	Any: Cele [1] 125/216 Cele [2] 136/207 Cele [3] 131/213 Naprox 131/207 Plac 123/217 GI-related: Cele [1] 36/216 Cele [2] 59/207 Cele [3] 63/213 Naprox 73 Placebo 39/217 Serious: Cele [1] 3/216 Cele [2] 2/207 Cele [3] 3/213 Naprox 3/207 Plac 7/217 Serious UGI: Cele [1] 1/216 Cele [2] 1/207 Cele [3] 0/213 Naprox 1/207 (GI Bleed) Plac 1/217 Serious CV: Cele [1] 0/216 Cele [2] 1/207 Cele [3] 1/213 Naprox 1/207 Plac 3/217	Dyspepsia: Cele [1] 8/216 Cele [2] 18/207 Cele [3] 21/213 Naprox 19/207 Plac 16/217 Abdom pain: Cele [1] 8/216 Cele [2] 11/207 Cele [3] 10/213 Naprox 19/207 Plac 6/217 Nausea : Cele [1] 8/216 Cele [2] 8/207 Cele [3] 12/213 Naprox 12/207 Placebo 5/217 Diarrhoea: Cele [1] 8/216 Cele [2] 13/207 Cele [3] 21/213 Naprox 11/207 Plac 12/217	Vomiting: Cele [1] 2/216 Cele [2] 3/207 Cele [3] 3/213 Naprox 2/207 Plac 0/217 Hemorrhagic Duodenal Ulcer: Cele [1] 0/216 Cele [2] 0/207 Cele [3] 0/213 Naprox 1/207 Plac 0/217	Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 10/216 Cele [2] 13/207 Cele [3] 16/213 Naprox 20/207 Plac 10/217	Generalised oedema: Cele [1] 0/216 Cele [2] 0/207 Cele [3] 1/213 Naprox 2/207 Plac 0/217 Peripheral Oedema: Cele [1] 3/216 Cele [2] 3/207 Cele [3] 11/213 Naprox 6/207 Plac 1/217 Facial oedema: Cele [1] 1/216 Cele [2] 1/207 Cele [3] 2/213 Naprox 0/207 Plac 0/217 Hypertension: Cele [1] 0/216 Cele [2] 1/207 Cele [3] 3/213 Naprox 1/207 Plac 0/217	Aggravated hypertension: Cele [1] 0/216 Cele [2] 1/207 Cele [3] 3/213 Naprox 1/207 Plac 0/217 MI: Cele [1] 0/216 Cele [2] 1/207 Cele [3] 1/213 Naprox 0/207 Plac 0/217 Cardiac Failure: Cele [1] 0/216 Cele [2] 0/207 Cele [3] 0/213 Naprox 1/207 Plac 1/217	Hct ≥5% decrease: Cele [1] 20/216 Cele [2] 9/207 Cele [3] 9/213 Naprox 27/207 Plac 14/217 Hb ≥20g/L decrease: Cele [1] 2/216 Cele [2] 0/207 Cele [3] 2/213 Naprox 4/207 Plac 1/217 Creatinine ≥1.3xULN: Cele [1] 3/216 Cele [2] 1/207 Cele [3] 4/213 Naprox 2/207 Plac 0/217	Any: Cele [1] 11/216 Cele [2] 20/207 Cele [3] 17/213 Naprox 22/207 Plac 9/217
C-060 OA 6 weeks	OA Knee (ACR) with flare FCC 1-3 Washout NSAID 2 days, other 5 half-lives Assessment at baseline, 2, 6 weeks Double dummy method QS 5/5; VS 16/16	Cele [1] 2x100mg/day (n=231) Cele [2] 1x200mg/day (n=222) Plac (n=231)	Cele [1] 37/231 Cele [2] 40/222 Plac 85/231	Cele [1] 18/231 Cele [2] 21/222 Plac 56/231	Cele [1] 11/231 Cele [2] 9/222 Plac 20/231 GI-related: Cele [1] 4/231 Cele [2] 3/222 Plac 9/231	Any: Cele [1] 122/231 Cele [2] 111/222 Plac 120/231 GI-related: Cele [1] 40/231 Cele [2] 37/222 Plac 32/231 Serious: Cele [1] 4/231 Cele [2] 0/222 Plac 5/231 Serious UGI: None Serious CV: Cele [1] 2/231 Cele [2] 0/222 Plac 0/231	Dyspepsia: Cele [1] 18/231 Cele [2] 12/222 Plac 10/231 Abdom pain: Cele [1] 4/231 Cele [2] 6/232 Placebo 7/231 Nausea: Cele [1] 5/231 Cele [2] 4/222 Placebo 12/231 Diarrhoea: Cele [1] 6/231 Cele [2] 10/222 Plac 7/231 Vomiting: Cele [1] 1/231 Cele [2] 0/222 Placebo 1/231		Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 4/231 Cele [2] 4/222 Plac 15/231	Peripheral oedema: Cele [1] 1/231 Cele [2] 7/222 Plac 5/231 Facial oedema: Cele [1] 1/231 Cele [2] 0/222 Plac 0/231 Hypertension: Cele [1] 3/231 Cele [2] 1/222 Plac 0/231 MI: Cele [1] 0/231 Cele [2] 0/222 Plac 1/231 Cardiac Failure: Cele [1] 2/231 Cele [2] 0/222 Plac 0/231		Hct ≥5% decrease: Cele [1] 13/231 Cele [2] 21/222 Plac 14/231 Hb ≥20g/L decrease: Cele [1] 1/231 Cele [2] 1/222 Plac 2/231 Creatinine 1.3xULN: Cele [1] 4/231 Cele [2] 2/222 Plac 4/231	Any: Cele [1] 8/231 Cele [2] 13/222 Plac 11/231
C-087 OA 6 weeks	OA Knee (ACR) flare FCC 1-3 Washout 2 days for NSAID Assessed at baseline, 2, 6 weeks. QS 5/5; VS 16/16	Cele [1] 2x100mg/day (n=241) Cele [2] 1x200mg/day (n=231) Plac (n=243)	Cele [1] 47/243 Cele [2] 40/231 Plac 79/243	Cele [1] 27/241 Cele [2] 24/231 Plac 55/243	Cele [1] 9/241 Cele [2] 6/231 Plac 12/243 GI-related: Cele [1] 3/241 Cele [2] 0/231 Plac 3/243	Any: Cele [1] 119/241 Cele [2] 124/231 Plac 116/243 GI-related: Cele [1] 49/241 Cele [2] 34/231 Plac 34/243 Serious: Cele [1] 0/241 Cele [2] 2/231 Plac 1/243 Serious UGI: None reported Serious CV: Cele [1] 0/241 Cele [2] 1/231 Plac 0/243	Dyspepsia: Cele [1] 15/241 Cele [2] 9/231 Plac 12/243 Abdom Pain: Cele [1] 5/241 Cele [2] 2/231 Plac 5/243 Nausea: Cele [1] 6/241 Cele [2] 7/231 Plac 5/243 Diarrhoea: Cele [1] 12/241 Cele [2] 7/231 Plac 3/243 Vomiting: Cele [1] 1/241 Cele [2] 1/231 Plac 1/243		Mod/severe dyspepsia, abdom pain, nausea: Cele [1] 9/241 Cele [2] 11/231 Plac 9/243	Generalised oedema: Cele [1] 0/241 Cele [2] 1/231 Plac 0/243 Peripheral oedema: Cele [1] 6/241 Cele [2] 6/231 Plac 2/243 Facial Oedema: Cele [1] 2/241 Cele [2] 0/231 Plac 2/243	Hypertension: Cele [1] 3/241 Cele [2] 0/231 Plac 0/243 Aggravated hypertension: Cele [1] 1/241 Cele [2] 4/231 Plac 2/243 No report of MI or CHF	Hct ≥5% decrease: Cele [1] 8/241 Cele [2] 8/231 Plac 5/243 Hb ≥20g/L decrease : Cele [1] 1/241 Cele [2] 3/231 Plac 1/243 Creatinine ≥1.3xULN: Cele [1] 6/241 Cele [2] 1/231 Plac 1/243	Any: Cele [1] 7/241 Cele [2] 12/231 Plac 11/243

C-096 OA 12 weeks	OA (ACR) hip/knee/hand ≥6 months, requiring NSAID/analgesic, FCC 1-3 Double dummy method Assessed baseline, 6, 12 weeks AEs assessed by investigator examination and question and patient reported and laboratory test QS 5/5; VS 16/16	Cele [1] 2x100mg/day (n=4393) Cele [2] 2x200mg/day (n=4407) Naprox 2x500mg/day (n=905) Diclo 2x50mg/day (n=3489)	Cele [1] 864/4393 Cele [2] 867/4407 Naprox 322/905 Diclo 530/3489	Cele [1] 240/4393 Cele [2] 177/4407 Naprox 79/905 Diclo 97/3489	Cele [1] 364/4393 Cele [2] 445/4407 Naprox 177/905 Diclo 274/3489 GI-related: Cele [1] 206/4393 Cele [2] 254/4407 Naprox 134/905 Diclo 163/3489	Any AE: Cele [1] 1601/4393 Cele [2] 1673/4407 Diclo 1257/3489 Naprox 515/905 GI-related: Cele [1] 704/4393 Cele [2] 762/4407 Diclo 604/3489 Naprox 320/905 Serious: Cele [1] 119/4393 Cele [2] 146/4407 Diclo 95/3489 Naprox 48/905 Serious UGI: Cele [1] 30/4393 Cele [2] 48/4407 Diclo 33/3489 Naprox 25/905	Dyspepsia: Cele [1] 189/4393 Cele [2] 234/4407 Diclo 162/3489 Naprox 97/905 Abdom Pain: Cele [1] 203/4393 Cele [2] 220/4407 Diclo 193/3489 Naprox 81/905 Nausea: Cele [1] 100/4393 Cele [2] 107/4407 Diclo 82/3489 Naprox 69/905 Diarrhoea: Cele [1] 148/4393 Cele [2] 159/4407 Diclo 117/3489 Naprox 47/905 Vomiting: Cele [1] 25/4393 Cele [2] 22/4407 Diclo 28/3489 Naprox 22/905	GIH: Cele [1] 2/4393 Cele [2] 1/4407 Diclo 1/3489 Naprox 1/905 Gastric ulcer: Cele [1] 1/4393 Cele [2] 4/4407 Diclo 1/3489 Naprox 3/905 Gastric ulcer haemorrhagic: Cele [1] 0/4393 Cele [2] 2/4407 Diclo 1/3489 Naprox 2/905 Duodenal ulcer: Cele [1] 1/4393 Cele [2] 0/4407 Diclo 0/3489 Naprox 0/905	Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 209/4393 Cele [2] 225/4407 Diclo 200/3489 Naprox 130/905	Generalised oedema: Cele [1] 33/4393 Cele [2] 9/4407 Diclo 8/3489 Naprox 8/905 Peripheral oedema: Cele [1] 69/4393 Cele [2] 60/4407 Diclo 28/3489 Naprox 35/905 Facial oedema: Cele [1] 10/4393 Cele [2] 11/4407 Diclo 8/3489 Naprox 1/905	Hypertension: Cele [1] 41/4393 Cele [2] 53/4407 Diclo 44/3489 Naprox 11/905 Aggravated hypertension: Cele [1] 10/4393 Cele [2] 15/4407 Diclo 10/3489 Naprox 2/905 Cardiac Failure: Cele [1] 2/4393 Cele [2] 2/4407 Diclo 7/3489 Naprox 2/905 MI: Cele [1] 8/4393 Cele [2] 2/4407 Diclo 0/3489 Naprox 1/905	Hb ≥20g/L decrease: Cele [1+2] 38/7251 Diclo+Naprox 31/3613 Hct ≥10% reduction: Cele [1+2] 8/6943 Diclo+Naprox 8/3462 Creatinine ≥1.3xULN: Cele [1+2] 13/7436 Diclo+Naprox 12/3701 (not all patients had haematological measurements)	Cele [1] 574/4393 Cele [2] 638/4407 Diclo 532/3489 Naprox 218/905
C-118 OA 6 weeks	OA knee (ACR) with flare FCC 1-3 Washout 2 days for NSAIDs, other 5 half-lives Assessed at baseline, 2, 6 weeks QS 5/5; VS 16/16	Cele 2x100mg/day (n=199) Diclo 3x50mg/day (n=199) Plac (n=200)	Cele 40/199 Diclo 37/199 Plac 71/200	Cele 18/199 Diclo 10/199 Plac 42/200	Cele 14/199 Diclo 22/199 Plac 14/200 GI-related not given	Any: Cele 99/199 Diclo 107/199 Plac 99/200 GI-related: Cele 35/199 Diclo 49/199 Plac 38/200 Serious: Cele 0/199 Diclo 4/199 Plac 1/200 Serious UGI: Cele 0/199 Diclo 0/199 Plac 1/200 Serious CV: Cele 0/199 Diclo 2/199 Plac 0/200	Dyspepsia: Cele 11/199 Diclo 15/199 Plac 12/200 Abdom pain: Cele 7/199 Diclo 14/199 Placebo 7/200 Nausea: Cele 4/199 Diclo 7/199 Plac 6/200 Diarrhoea: Cele 9/199 Diclo 13/199 Placebo 10/200 Vomiting: Cele 1/199 Diclo 2/199 Plac 0/200	Gastric ulcer: Cele 0/199 Diclo 1/199 Plac 0/200	Mod/severe dyspepsia, abdom pain, nausea: Cele 2/199 Diclo 13/199 Plac 10/200	Generalised oedema: Cele 0/199 Diclo 1/199 Placebo 0/200 Peripheral oedema: Cele 10/199 Diclo 5/199 Placebo 1/200 Hypertension: Cele 1/199 Diclo 2/199 Placebo 0/200 Aggravated hypertension: Cele 0/199 Diclo 2/199 Placebo 1/200	No report of MI or CHF	Hct ≥5% decrease: Cele 15/199 Diclo 23/199 Plac 17/200 Hb ≥20g/L decrease: Cele 1/199 Diclo 2/199 Plac 1/200 Creatinine ≥1.3XULN: Cele 1/199 Diclo 1/199 Placebo 1/200	Any: Cele 16/199 Diclo 24/199 Plac 19/200
C-149 OA 6 weeks	OA Hand/Knee/Hip (ACR), requiring NSAID and/or analgesic, with treated stable hypertension FCC 1-3 Washout 4 days Double dummy method Assessment baseline, 1, 2, 6 weeks. QS 5/5; VS 16/16	Cele 1x200mg/day (n=411) Rofe 1x25mg/day (n=399)	Cele 64/411 Rofe 51/399	Cele 8/411 Rofe 4/399	All: Cele 37/411 Rofe 36/399 GI-related: Cele 11/411 (1 GI Bleed) Rofe 16/399 (1 GI Bleed)	Excluding renal Any: Rofe 237/411 Rofe 245/399 All Serious Cele 11/411(1 GIH) Rofe 10/399 GI related: Cele 67/411 Rofe 86/399 Serious UGI: Cele 2/411 Rofe 0/399 Any "renal event" (defined): Cele 129/411 Rofe 162/399 Composite renal event (defined): Cele 47/411 Rofe 72/399	Dyspepsia: Cele 21/411 Rofe 29/399 Diarrhoea: Cele 17/411 Rofe 22/399 Abdom Pain: Cele 13/411 Rofe 20/399 Nausea: Cele 8/411 Rofe 11/399 Possible others frequency ≤2%		Mod/severe abdom pain, nausea, dyspepsia: Cele 13/411 Rofe 26/399	Defined cardio-renal events: Primary outcomes Significant oedema: Cele 20/411 Rofe 38/399 Aggravated hypertension: Cele 23/411 Rofe 32/399 Composite renal events: Cele 47/411 Rofe 72/399 Secondary outcomes New/worsening oedema: Cele 78/411 Rofe 114/399 Elevated hypertension: Cele 58/411 Rofe 79/399 New/worsening CHF: Cele 0/411 Rofe 4/399	Lab result: Cele 6/411 Rofe 6/399 Any renal event: Cele 129/411 Rofe 162/399 Not meeting above definitions: Peripheral oedema: Cele 5/411 Rofe 10/399 Hypertension: Cele 1/411 Rofe 0/399 Aggravated hypertension: Cele 1/411 Rofe 4/399 Cardiac Failure: Cele 0/411 Rofe 1/399 MI: Cele 1/411 Rofe 0/399	Lab test = renal event: Cele 6/411 Rofe 6/399 Hb ≥20g/L: Cele 0/411 Rofe 1/399 Hct ≥5% decrease: Cele 59/411 Rofe 76/399 No clin relevant creatinine values reported	Cele 27/411 Rofe 36/399
C-152 OA 6 weeks	OA Knee (ACR) with flare, requiring NSAID ± analgesic FCC 1-3 Washout ≥2days Double dummy method Assessed at baseline, 3, 6 weeks QS 5/5; VS 16/16	Cele 1x200mg/day (n=63) Rofe 1x25mg/day (n=59) Plac (n=60)	Cele 14/63 Rofe 10/59 Plac 16/60	Cele 5/63 Rofe 2/59 Plac 12/60	All: Cele 4/63 Rofe 4/59 Plac 1/60 GI Related: Cele 1/63 Rofe 4/59 Plac 0/60	Any AE: Cele 31/63 Rofe 36/59 Plac 25/60 GI-related: Cele 7/63 Rofe 20/59 Plac 6/60 Serious: Cele 1/63 Rofe 0/59 Plac 0/60 Serious UGI: None	Dyspepsia: Cele 2/63 Rofe 6/59 Plac 4/60 Abdom Pain: Cele 1/63 Rofe 6/59 Plac 0/60 Nausea: Cele 1/63 Rofe 1/59 Plac 0/60 Diarrhoea: Cele 3/63 Rofe 4/59 Plac 0/60 Vomiting: Cele 1/63 Rofe 0/59 Plac 0/60		Mod/severe abdom pain, nausea, dyspepsia: Cele 3/63 Rofe 5/59 Plac 0/60	Peripheral oedema: Cele 2/63 Rofe 2/59 Plac 1/60 Hypertension: Cele 2/63 Rofe 0/59 Plac 0/60 Aggravated hypertension: Cele 1/63 Rofe 1/59 Plac 1/60 No report of MI or CHF		Hb ≥10g/L: Cele 3/63 Rofe 5/59 Plac 0/60 Creatinine ≥1.3xULN: None Ht ≥5% decrease: Cele 0/63 Rofe 2/59 Plac 0/60 No withdrawals due to lab test results	All AEs: Cele 4/63 Rofe 6/59 Placebo 0/60 No serious adverse event related to study medication
C-181 OA 6 weeks	OA (ACR) Hand/Knee/Hip, requiring NSAID or analgesic, with stable treated hypertension FCC 1-3 Washout 4 days Double dummy method Assessed at baseline, 1, 2, 6 weeks QS 5/5; VS 16/16	Cele 1x200mg/day (n=549) Rofe 1x25mg/day (n=543)	Cele 51/549 Rofe 53/543	Cele 4/549 Rofe 3/543	All: Cele 26/549 Rofe 27/543 GI Related: Cele 11/549 Rofe 15/543 Cardio renal: Cele 8/549 Rofe 12/543	Excluding cardiorenal Any AE: Cele 251/549 Rofe 249/543 Serious: Cele 12/549 Rofe 11/543 (cardiac failure 3) GI-related: Cele 83/549 Rofe 83/543 Serious UGI: Cele 3/549 (Bleeds) Rofe 1/543 (Perforation) Any defined cardiorenal events: Cele 142/549 Rofe 195/543	Dyspepsia: Cele 24/549 Rofe 19/543 Abdom Pain: Cele 14/549 Rofe 22/543 Diarrhoea: Cele 21/549 Rofe 17/543 Any others occurred at frequency <2%		Mod/severe abdom pain, nausea, dyspepsia: Cele 16/549 Rofe 9/543	Defined cardio-renal events: Diastolic BP: Cele 7/549 Rofe 12/543 Systolic BP: Cele 6.9% Rofe 14.9% Oedema: Cele 101/549 Rofe 136/543 Cardiac Failure: Cele 2/549 Rofe 3/543	Not meeting above definitions: Aggravated hypertension: Cele 18/549 Rofe 19/543 Oedema: Cele 26/549 Rofe 18/543	Data not available	Data not available
C-209 OA 6 weeks	OA (ACR) knee with flare, requiring daily therapy, FCC 1-3 Double dummy method Assessed at baseline, 2, 6 weeks AEs observed or patient reported and laboratory tests QS 5/5; VS 16/16	Cele 1x200mg/day (n=125) Naprox 2x500mg/day (n=125) Plac (n=66)	Cele 23/125 Naprox 18/125 Plac 22/66	Cele 2/125 Naprox 2/125 Plac 10/66	Cele 7/125 Naprox 7/125 Placebo 2/66	Any AE: Cele 52/125 Naprox 51/125 Plac 35/66 GI-related: Cele 0/125 Naprox 6/125 Plac 4/66 Serious: Cele 1/125 Naprox 1/125 Plac 0/66 Serious UGI: Cele 0/125 Naprox 0/125 Plac 0/66	Dyspepsia: Cele 1/125 Naprox 4/125 Plac 3/66 Abdom Pain: Cele 1/125 Naprox 3/125 Plac 3/66 Nausea: Cele 2/125 Naprox 3/125 Plac 2/66 Diarrhoea: Cele 3/125 Naprox 2/125 Plac 1/66	Vomiting: ≤2% in any group	Mod/severe abdom pain, nausea, dyspepsia: Cele 0/125 Naprox 6/125 Plac 4/66	oedema and hypertension: <2% in any group		Some "abnormal results" for Hb, Ht and creatinine One withdrawal due to lab test (Naprox)	Cele 32/125 Naprox 42/125 Plac 27/66 2 serious AEs were not treatment related

C-210 OA 6 weeks	OA Knee (ACR) with flare, requiring chronic NSAID/analgesic, FCC 1-3 Initial pain 40-100mm VAS. Washout>2 days Assessed at baseline, 2, 6 weeks double-dummy method AEs observed by investigator and patient reported and laboratory tests QS 5/5; VS 16/16	Cele 1x200mg/day (n=145) Naprox 2x500mg/day (n=141) Plac (n=76)	Cele 27/145 Naprox 39/141 Plac 19/76	Cele 0/145 Naprox 0/141 Plac 5/76	Cele 10/145 Nap 15/141 Plac 3/76	Any AE: Cele 40/145 Naprox 65/141 Plac 22/76 GI related: details not available Serious: No serious AEs Serious UGI: No serious UGI AEs	Dyspepsia: Cele 1% Naprox 4% Plac 0% Abdom pain: Cele 8% Naprox 12% Plac 4% Details of other outcomes not available		Mod/severe abdom pain, nausea, dyspepsia: Cele 5/145 Naprox 9/141 Plac 2/76	oedema and hypertension in <2% in any treatment group		Abnormalities seen in Hct, Hb and creatinine No withdrawals	Cele 19/145 Naprox 34/141 Plac 6/76 Withdrawals: Cele 7/145 Nap 12/141 Placebo 1/76
C-211 OA 6 weeks	OA Knee with flare (ACR) requiring NSAID therapy Initial pain 40-90 on 100mm VAS Washout >2 day Double dummy method Assessed at baseline, 2, 6 weeks AEs investigator observed and patient reported and laboratory tests QS 5/5; VS 16/16	Cele 1x200mg/day (n=125) Naprox 2x500mg/day (n=129) Plac (n=61)	Cele 30/125 Naprox 36/129 Plac 16/61	Cele 2/125 Naprox 3/129 Plac 5/61	Cele 3/125 Naprox 9/129 Plac 1/61	Any AE: Cele 46/125 Naprox 47/129 Plac 17/61 GI related: data not available Serious: Cele 0/125 Naprox 1/129 Placebo 0/61 Serious UGI: Cele 0/125 Naprox 1/129 (GI bleed) Plac 0/61	Dyspepsia: Cele 4/125 Naprox 5/129 Plac 1/61 Abdom pain: Cele 2/125 Naprox 4/129 Plac 0/61 Details of other outcomes not available		Mod/severe abdom pain, nausea, dyspepsia: Cele 3/125 Naprox 4/129 Plac 1/61	Not available		Not available	All AEs: Cele 17/125 Naprox 26/129 Plac 7/61 Withdrawals: Cele 2/125 Naprox 7/129 Plac 1/61
C-216 OA 4 weeks	Symptomatic OA (X-ray confirmed) of Knee, requiring NSAID Initial pain ≥40 on 100 mm VAS Double dummy method Assessed at baseline, 2, 4 weeks AEs observed by investigator and laboratory tests QS 5/5; VS 16/16	Cele 2x100mg/day (n=382) Loxo 3x60mg/day (n=385) Plac (n=192)	Cele 35/382 Naprox 36/385 Plac 15/192	Cele 6/382 Loxo 3/385 Plac 4/192	Cele 21/382 Loxo 24/385 Plac 7/192	Any AE: Cele 203/382 Loxo 216/384 Plac 100/192 GI-related: Cele 104/382 Loxo 98/384 Plac 44/192 Serious: Cele 1/382 Loxo 5/384 Plac 1/192 Serious UGI: Cele 0/382 Loxo 0/384 Plac 0/192	Dyspepsia: Cele 7/382 Loxo 7/384 Plac 4/192 Abdom Pain: Cele 35/382 Loxo 20/384 Plac 9/192 Nausea: Cele 6/382 Loxo 3/384 Plac 3/192 Diarrhoea: Cele 14/382 Loxo 19/384 Plac 5/192 Vomiting: Cele 1/382 Loxo 1/384 Plac 0/192	Gastric ulcer: Cele 0/382 Loxo 2/384 Placebo 0/192 Duodenal ulcer: Cele 0/382 Loxo 1/384 Placebo 0/192 GIH: Cele 0/382 Loxo 2/384 (but not serious) Placebo 0/193	Mod/severe abdom pain, nausea, dyspepsia: Cele 10/382 Loxo 9/384 Plac 3/192	Generalised Oedema: Cele 0/382 Loxo 6/384 Plac 1/192 Periph Oedema: Cele 0/382 Loxo 4/384 Plac 0/192 Facial Oedema: Cele 2/382 Loxo 9/384 Plac 0/192 Hypertension: Cele 2/382 Loxo 2/384 Placebo 0/192 Aggravated hypertension: Cele 0/382 Loxo 0/384 Placebo 1/192	Trial did not report any cases of heart failure Trial did not report any cases of MI	Hb ≥30g/L decrease: Cele 0/382 Loxo 1/372 Plac 0/192 Hct ≥10% decrease: Cele 0/382 Loxo 0/372 Plac 0/192 Creatinine ≥300 micromol/L: Cele 4/363 Loxo 7/366 Plac 2/186	Cele 124/382 Loxo 152/384 Plac 60/192 No serious adverse events were related to the study medication
C-249 OA 2x6 week crossover	OA Hip/Knee (K-L 2-4), requiring chronic NSAID/analgesic Initial pain 40-90 on 100mm (VAS) Washout between treatments 3-7 days Double dummy method Two periods each assessed at baseline and six weeks AEs investigator reported and laboratory tests QS 5/5; VS 16/16	Cele 1x200mg/day (n1=189) (n2=184) Para 4x1000mg/day (n1=185) (n2=146) Plac (n1=182) (n2=91)	Period 1: Cele 36/189 Para 64/185 Plac 68/182 Period 2: Cele 15/184 Para 17/146 Placebo 20/91	Period 1: Cele 20/189 Para 28/185 Plac 41/182 Period 2: Cele 6/184 Para 10/146 Plac 16/91	Period 1: Cele 9/189 Para 8/185 Plac 7/182 GI-related: Cele 1/189 Para 4/185 Placebo 4/182 Period 2: Cele 4/184 Para 4/146 Plac 1/91	Period 1: Any AE: Cele 56/189 Para 57/185 Placebo 45/182 GI-related: Cele 20/189 Para 21/185 Placebo 13/182 Serious: Cele 1/189 Para 1/185 Placebo 1/182 No serious UGI Period 2: Any AE: Cele 47/184 Para 30/146 Placebo 18/91 GI-related: Cele 15/184 Para 9/146 Placebo 4/91 Serious: Cele 1/184 Para 0/146 Placebo 0/91 No serious UGI	Period 1: Dyspepsia: Cele 3/189 Para 6/185 Placebo 2/182 Abdom Pain: Cele 3/189 Para 6/185 Placebo 5/182 Nausea: Cele 6/189 Para 3/185 Placebo 3/182 Diarrhoea: Cele 3/189 Para 9/185 Placebo 3/182 Vomiting: Cele 1/189 Para 1/185 Placebo 1/182	Period 2: Dyspepsia: Cele 3/184 Para 0/146 Placebo 0/91 Abdom Pain: Cele 1/184 Para 0/146 Placebo 1/91 Nausea: Cele 2/184 Para 1/146 Placebo 0/91 Diarrhoea: Cele 3/184 Para 0/146 Placebo 0/91 Vomiting: Cele 2/184 Para 0/146 Placebo 0/91	Period 1: Mod/severe abdom pain, nausea, dyspepsia: Cele 3/189 Para 7/185 Placebo 6/182 Periods I and 2 combined: Mod/severe abdom pain, nausea, dyspepsia: Cele 5/373 Para 3/331 Placebo 6/273	Period 1: Generalised Oedema: Cele 5/189 Para 3/185 Placebo 2/182 Facial Oedema: Cele 0/189 Para 1/185 Placebo 0/182 Hypertension: Cele 0/189 Para 1/185 Placebo 0/182 Aggravated hypertension: Cele 1/189 Para 1/185 Placebo 0/182 Trial did not report any cases of heart failure Trial did not report any cases of MI	Period 2: Perip Oedema: Cele 4/184 Para 3/146 Placebo 0/91 Facial Oedema: Cele 0/184 Para 1/146 Placebo 0/91 No report of hypertension	Hct: essentially unchanged Hb: small changes, NS between groups No clinically significant findings in either Period 1 or period 2	Period 1: data not provided Periods I and 2 combined All AEs: Cele 26/373 Para 22/331 Placebo 14/273
Rheumatoid arthritis													
C-012 RA 4 weeks	RA (ACR) (min 6 months) requiring NSAID FCC 1-3 Assessment at baseline, 1, 2, 4 weeks Double dummy method Washout 2 to 7 days QS 5/5; VS 16/16	Cele [1] 2x40mg/day (n=80) Cele [2] 2x200mg/day (n=82) Cele [3] 2x400mg/day (n=81) Plac (n=84)	Cele [1] 18/80 Cele [2] 9/82 Cele [3] 10/81 Plac 25/84	Cele [1] 14/80 Cele [2] 3/82 Cele [3] 5/81 Plac 15/84	Cele [1] 3/80 Cele [2] 4/82 Cele [3] 4/81 Plac 5/84	Any: Cele [1] 45/80 Cele [2] 48/82 Cele [3] 43/81 Plac 53/84 GI -related: Cele [1] 19/80 Cele [2] 16/82 Cele [3] 18/81 Placebo 14/84 Serious: None No serious UGI No serious CV	Dyspepsia: Cele [1] 9/80 Cele [2] 6/82 Cele [3] 2/81 Plac 1/84 Abdom Pain: Cele [1] 4/80 Cele [2] 2/82 Cele [3] 2/81 Plac 4/84 Nausea: Cele [1] 3/80 Cele [2] 3/82 Cele [3] 4/81 Plac 5/84 Diarrhoea: Cele [1] 5/80 Cele [2] 4/82 Cele [3] 9/81 Plac 2/84 Vomiting: Cele [1] 1/80 Cele [2] 2/82 Cele [3] 1/81 Plac 0/84		Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 12/80 Cele [2] 5/82 Cele [3] 2/81 Plac 3/84	Generalised oedema: Cele [1] 0/80 Cele [2] 0/80 Cele [3] 1/81 Placebo 0/84 Peripheral Oedema: Cele [1] 2/80 Cele [2] 1/82 Cele [3] 2/81 Plac 0/84 Facial Oedema: Cele [1] 2/80 Cele [2] 2/82 Cele [3] 1/81 Plac 1/84	Hypertension: Cele [1] 0/80 Cele [2] 1/80 Cele [3] 0/81 Plac 0/84 Aggravated hypertension: Cele [1] 0/80 Cele [2] 1/80 Cele [3] 0/81 Plac 0/84	No clinically important laboratory abnormalities were noted	Cele [1] 9/80 Cele [2] 5/82 Cele [3] 8/81 Plac 6/84
C-022 RA 12 weeks	RA (ACR) (min 3 months) with flare, requiring NSAID FCC 1-3 Assessment at baseline, 2, 6, 12 weeks Endoscopy at 12 weeks Washout 2-7 days Double dummy method QS 5/5; VS16/16	Cele [1] 2x100mg/day (n=240) Cele [2] 2x200mg/day (n=235) Cele [3] 2x400mg/day (n=218) Naprox 2x500mg/day (n=225) Placebo (n=231)	Cele [1] 86/240 Cele [2] 77/235 Cele [3] 81/218 Naprox 87/225 Plac 130/231	Cele [1] 67/240 Cele [2] 50/235 Cele [3] 59/218 Naprox 65/225 Plac 104/231	Cele [1] 13/240 Cele [2] 17/235 Cele [3] 12/218 Naprox 12/225 Plac 11/231	Any: Cele [1] 164/240 Cele [2] 149/235 Cele [3] 135/217 Naprox 147/225 Plac 128/231 GI-related: Cele [1] 66/240 Cele [2] 59/235 Cele [3] 57/217 Naprox 69/225 Plac 45/231 Serious: Cele [1] 4/240 Cele [2] 4/235 Cele [3] 4/217 Naprox 3/225 Plac 5/231 Serious UGI: Cele [1] 0/240 Cele [2] 0/235 Cele [3] 0/217 Naprox 1/225 Plac 0/231 Serious CV: Cele [1] 1/240 Cele [2] 2/235 Cele [3] 1/217 Naprox 0/225 Plac 2/231	Dyspepsia: Cele [1] 24/240 Cele [2] 22/235 Cele [3] 22/217 Naprox 26/225 Plac 16/231 Plac 8/231 Abdom pain: Cele [1] 9/240 Cele [2] 9/235 Cele [3] 10/217 Naprox 15/225 Plac 6/231 Nausea: Cele [1] 10/240 Cele [2] 8/235 Cele [3] 7/217 Naprox 10/225 Plac 12/231 Diarrhoea: Cele [1] 13/240 Cele [2] 14/235 Cele [3] 15/217 Naprox 10/225	Vomiting: Cele [1] 3/240 Cele [2] 2/235 Cele [3] 4/217 Naprox 3/225 Plac 2/231 Gastric Ulcer: Cele [1] 0/240 Cele [2] 1/235 Cele [3] 0/217 Naprox 1/225 Plac 0/231	Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 18/246 Cele [2] 17/235 Cele [3] 16/217 Naprox 26/225 Plac 14/231	Generalised Oedema: Cele [1] 1/240 Cele [2] 0/235 Cele [3] 1/217 Naprox 3/225 Plac 0/231 Peripheral Oedema: Cele [1] 3/240 Cele [2] 5/235 Cele [3] 5/217 Naprox 4/225 Plac 0/231 Facial Oedema: Cele [1] 0/240 Cele [2] 1/235 Cele [3] 0/217 Naprox 1/225 Plac 1/231 Hypertension: Cele [1] 0/240 Cele [2] 1/235 Cele [3] 2/217 Naprox 1/225 Plac 1/231	MI: Cele [1] 0/240 Cele [2] 1/235 Cele [3] 0/217 Naprox 0/225 Plac 1/231 Cardiac failure: no report of CF	Hct ≥5% decrease: Cele [1] 23/240 Cele [2] 29/235 Cele [3] 39/217 Naprox 32/225 Plac 22/231 Hb ≥20g/L decrease: Cele [1] 1/240 Cele [2] 2/235 Cele [3] 4/217 Naprox 4/225 Plac 0/231	Cele [1] 20/240 Cele [2] 23/235 Cele [3] 19/217 Naprox 29/225 Plac 13/231

C-023 RA 12 weeks	RA (ACR) (min 3 months) with flare requiring NSAID FCC 1-3 Assessment at baseline, 2, 6, 12 weeks Washout 2-7 days Double dummy method. QS 5/5; VS 16/16	Cele [1] 2x100mg/day (n=228) Cele [2] 2x200mg/day (n=218) Cele [3] 2x400mg/day (n=217) Naprox 2x500mg/day (n=218) Placebo (n=221)	Cele [1] 111/228 Cele [2] 94/218 Cele [3] 91/217 Naprox 85/218 Plac 143/221	Cele [1] 92/228 Cele [2] 74/218 Cele [3] 69/217 Naprox 69/218 Plac 125/221	Cele [1] 12/228 Cele [2] 16/218 Cele [3] 16/217 Naprox 16/218 Plac 12/221	Any: Cele [1] 130/228 Cele [2] 126/218 Cele [3] 134/217 Naprox 133/218 Plac 114/221 GI-related: Cele [1] 52/228 Cele [2] 51/218 Cele [3] 52/217 Naprox 61/218 Plac 39/221 Serious: Cele [1] 2/228 Cele [2] 1/218 Cele [3] 2/217 Naprox 3/218 Plac 2/221 Serious UGI: Cele [1] 0/228 Cele [2] 0/218 Cele [3] 0/217 Naprox 1/218 Placebo 2/221 Serious CV: Cele [1] 1/228 Cele [2] 0/218 Cele [3] 2/217 Naprox 1/218 Plac 0/221	Dyspepsia: Cele [1] 23/228 Cele [2] 18/218 Cele [3] 16/217 Naprox 29/218 Plac 13/221 Abdom pain: Cele [1] 10/228 Cele [2] 4/218 Cele [3] 5/217 Naprox 11/218 Plac 6/221 Nausea : Cele [1] 8/228 Cele [2] 7/218 Cele [3] 11/217 Naprox 8/218 Plac 11/221	Diarrhoea: Cele [1] 13/228 Cele [2] 10/218 Cele [3] 13/217 Naprox 8/218 Plac 10/221 Vomiting: Cele [1] 1/228 Cele [2] 2/218 Cele [3] 7/217 Naprox 3/218 Plac 3/221	Mod/severe abdom pain, nausea, dyspepsia: Cele [1] 17/228 Cele [2] 8/218 Cele [3] 11/217 Naprox 20/218 Plac 13/221	Generalised oedema: Cele [1] 0/228 Cele [2] 0/218 Cele [3] 0/217 Naprox 2/218 Plac 0/221 Peripheral oedema: Cele [1] 3/228 Cele [2] 3/218 Cele [3] 6/217 Naprox 2/218 Plac 4/221 Facial oedema: Cele [1] 1/228 Cele [2] 1/218 Cele [3] 1/217 Naprox 0/218 Plac 2/221	Hypertension: Cele [1] 0/228 Cele [2] 2/218 Cele [3] 1/217 Naprox 0/218 Plac 1/221 Aggravated hypertension: Cele [1] 1/228 Cele [2] 1/218 Cele [3] 2/217 Naprox 2/218 Plac 1/221 MI: Cele [1] 1/228 Cele [2] 0/218 Cele [3] 1/217 Naprox 0/218 Plac 0/221 Cardiac failure: Cele [1] 0/228 Cele [2] 0/218 Cele [3] 0/217 Naprox 1/218 Plac 0/221	Hct ≥5% decrease: Cele [1] 15/228 Cele [2] 15/218 Cele [3] 21/217 Naprox 16/218 Plac 11/221 Hb ≥20g/L decrease: less than 1% of patients	Cele [1] 17/228 Cele [2] 12/218 Cele [3] 20/217 Naprox 24/218 Plac 15/221
C-041 RA 6 months	RA (ACR) (min 6 months) requiring NSAID FCC 1-3 Assessment at baseline, weeks, 4, 8, 12, 16, 20 and 24 weeks Endoscopy 24 weeks Washout? - no investig drug <30days Double dummy method QS 5/5; VS 16/16	Cele 2x200mg/day (n=326) Diclo SR 2x75mg/day (n=329)	Cele 68/326 Diclo 94/329	Cele 26/326 Diclo 22/329	Cele 34/326 Diclo 64/329	Any: Cele 222/326 Diclo 239/329 GI-related: Cele 118/326 Diclo 159/329 Serious: Cele 14/326 Diclo 16/329 Serious UGI: Cele 0/326 Diclo 5/329 (Gastric ulcer =1; GI bleed =1) Serious CV: Cele 1/326 Diclo 1/329	Dyspepsia: Cele 32/326 Diclo 42/329 Abdom pain: Cele 36/326 Diclo 68/329 Nausea: Cele 15/326 Diclo 27/329 Diarrhoea: Cele 39/326 Diclo 46/329 Vomiting: Cele 6/326 Diclo 17/329	Duodenal ulcer: Cele 2/326 Diclo 7/329 Gastric ulcer: Cele 0/326 Diclo 9/329 Haemorrhagic Gastritis: Cele 0/326 Diclo 1/329	Mod/severe abdom pain, nausea, dyspepsia: Cele 31/326 Diclo 77/329	Generalised oedema: Cele 0/326 Diclo 2/329 Peripheral oedema: Cele 11/326 Diclo 5/329 Facial oedema: Cele 1/326 Diclo 2/329 Hypertension: Cele 4/326 Diclo 5/329 MI: Cele 1/326 Diclo 0/329 Cardiac failure: Cele 2/326 Diclo 1/329		Hct ≥5% decrease: Cele 25/326 Diclo 57/329 Hb ≥20g/L decrease: Cele 14/326 Diclo 18/329 Creatinine ≥1.3xULN: Cele 4/326 Diclo 2/329	Cele 74/326 Diclo 97/329
Osteoarthritis and rheumatoid arthritis														
C-062 OA/RA 12 weeks	OA/RA (ACR) (min 3 months) with flare FCC 1-3 Assessed (including endoscopy) at baseline, 4, 8, 12 weeks Washout ≥30 days for naprox QS 5/5, VS 16/16	Cele 2x200mg/day (n=269) Naprox 2x500mg/day (n=267)	Cele 59/269 Naprox 118/267	Cele 17/269 Naprox 11/267	Cele 19/269 Naprox 24/267 GI-related: Cele 11/269 Naprox 16/267 plus endoscopic ulcer: Cele 12/269 Naprox 67 /267	Any: Cele 188/269 Naprox 186/267 Serious: Cele 8/269 Naprox 8/267 GI-related: Cele 92/269 Naprox 107/267 Serious UGI: Cele 1/269 Naprox 1/267 Serious CV: Cele 2/269 Naprox 2/267	Dyspepsia: Cele 34/269 Naprox 28/267 Abdom Pain: Cele 23/269 Naprox 33/267 Nausea: Cele 8/269 Naprox 23/267 Diarrhoea: Cele 21/269 Naprox 17/267 Vomiting: Cele 6/269 Naprox 4/267	Duodenal ulcer: Cele 2/269 Naprox 2/267 Gastric ulcer: Cele 1/269 Naprox 1/267 Haemorrhagic Gastritis: Cele 1/269 Naprox 1/267 Peptic ulcer: Cele 0/269 Naprox 1/267	Mod/severe abdom pain, nausea, dyspepsia: Cele 20/269 Naprox 35/267	Peripheral oedema: Cele 8/269 Naprox 8/267 Hypertension: Cele 5/269 Naprox 3/267 Aggravated hypertension: Cele 1/269 Naprox 1/267 Anaemia: Cele 0/269 Naprox 4/267	MI: Cele 1/269 Naprox 1/267 No report of CHF	Hct ≥5% decrease: Cele 35/269 Naprox 29/267 Hb ≥20g/L: Cele 6/269 Naprox 7/267 Creatinine ≥1.3xULN: Cele 3/269 Naprox 1/267 No lab findings considered clinically sig and no pattern suggesting any changes due to drug-related process	Cele 29/269 Naprox 49/267
C-071 OA/RA 12 weeks	OA/RA (ACR) (min 3 months) requiring NSAID FCC 1-3 Assessed (including endoscopy) at baseline, 4, 8, 12 weeks Washout ≥30 days for chronic diclo or ibu QS 5/5; VS 16/16	Cele 2x200mg/day (n=365) Diclo 2x75mg/day (n=387) Ibu 3x800mg/day (n=345)	Cele 77/365 Diclo 99/387 Ibu 115/345	Cele 18/365 Diclo 10/387 Ibu 14/345	Cele 22/365 Diclo 37/387 Ibu 37/345 GI-related: Cele 11/365 Diclo 22/387 Ibu 26/345 plus endoscopic ulcers: Cele 19/365 Diclo 27/387 Ibu 47/345	Any: Cele 214/365 Diclo 258/387 Ibu 237/345 GI-related: Cele 110/365 Diclo 140/387 Ibu 131/345 Serious: Cele 9/365 Diclo 8/387 Ibu 4/345 Serious UGI: Cele 1/365 (GIH) Diclo 0/387 Ibu 0/345	Dyspepsia: Cele 34/365 Diclo 42/387 Ibu 44/345 Abdom pain: Cele 22/365 Diclo 35/387 Ibu 31/345 Nausea: Cele 12/365 Diclo 13/387 Ibu 23/345 Diarrhoea: Cele 20/365 Diclo 36/387 Ibu 20/345	Vomiting: Cele 5/365 Diclo 8/387 Ibu 6/345 Gastric ulcer: Cele 0/365 Diclo 0/387 Ibu 4/345 Gastric ulcer Haemorrhagic: Cele 1/365 Diclo 0/387 Ibu 1/345	Mod/severe abdom pain, nausea, dyspepsia: Cele 33/365 Diclo 49/387 Ibu 40/345	Peripheral oedema: Cele 6/365 Diclo 4/387 Ibu 12/345 Facial oedema: Cele 1/365 Diclo 1/387 Ibu 2/345 Generalised oedema: Cele 0/365 Diclo 1/387 Ibu 0/345 Hypertension: Cele 5/365 Diclo 2/387 Ibu 2/345	Aggravated hypertension: Cele 2/365 Diclo 0/387 Ibu 0/345 Cardiac Failure: Cele 1/365 Diclo 0/387 Ibu 0/345 MI: Cele 0/365 Diclo 0/387 Ibu 1/345	Hct ≥5% decrease: Cele 77/365 Diclo 103/387 Ibu 106 /345 Hb ≥20g/L decrease: Cele 11/365 Diclo 10/387 Ibu 15/345 Creatinine ≥1.3xULN: Cele 2/365 Diclo 4/387 Ibu 8/345 No lab findings considered clinically sig and no pattern suggesting any changes due to drug-related process	Cele 28/365 Diclo 49/387 Ibu 52/345
C-102 OA/RA 52 weeks	OA/RA (documented) (min 3 months) requiring NSAID Assessed at baseline 13,26,39, 52 weeks Washout 30 days QS 5/5; VS 16/16	Cele 2x400mg/day (n=3987) Ibu 3x800 mg/day (n=1985) Diclo 2x75mg/day (n=1996)	Cele 2208/3987 Ibu 1294/1985 Diclo 1057/1996	Cele 2208/3987 Ibu 1294/1985 Diclo 1057/1996	Any: Cele 892/3987 Ibu 456/1985 Diclo 529/1996 GI-related: Cele 487/3987 Ibu 266/1985 Diclo 331/1996	Any: Cele 3260/3987 Ibu 1579/1985 Diclo 1654/1996 GI-related: Cele 1819/3987 Ibu 917/1985 Diclo 1097/1996 Serious: Cele 270/3987 Ibu 119/1985 Diclo 111/1996 Serious UGI: Cele 44/3987 Ibu 19/1985 Diclo 23/1996	Dyspepsia: Cele 659/3987 Ibu 328/1985 Diclo 390/1996 Abdom Pain: Cele 466/3987 Ibu 225/1985 Diclo 370/1996 Nausea: Cele 328/3987 Ibu 178/1985 Diclo 242/1996 Diarrhoea: Cele 434/3987 Ibu 148/1985 Diclo 299/1996 Vomiting: Cele 103/3987 Ibu 53/1985 Diclo 69/1996	Duodenal Ulcer: Cele 17/3987 Ibu 6/1985 Diclo 8/1996 Duodenal bleeding: Cele 0/3987 Ibu 1/1985 Diclo 1/1996 Gastric Ulcer: Cele 21/3987 Ibu 25/1985 Diclo 16/1996 Gastric bleeding: Cele 5/3987 Ibu 2/1985 Diclo 0/1996 GIH: Cele 9/3987 Ibu 2/1985 Diclo 2/1996	Clin sig UGI event (Trad definition) Cele 20/3987 Ibu 13/1985 Diclo 11/1996	Generalised Oedema: Cele 19/3987 Ibu 20/1985 Diclo 11/1996 Peripheral Oedema: Cele 146/3987 Ibu 104/1985 Diclo 70/1996 Facial Oedema: Cele 21/3987 Ibu 8/1985 Diclo 4/1996 Hypertension: Cele 78/3987 Ibu 61/1985 Diclo 40/1996 Aggravated Hypertension: Cele 32/3987 Ibu 24/1985 Diclo 12/1996	Cardiac Failure: Cele 12/3987 Ibu 9/1985 Diclo 3/1996 MI: Cele 19/3987 Ibu 9/1985 Diclo 5/1996	Hct =0.25 or ≥10% decrease: Cele 4/3701 Ibu 2/1802 Diclo 5/1849 Hb <6 or 30g/L decrease: Cele 9/3708 Ibu 7/1805 Diclo 9/1851 Creatinine >300 U/L: Cele 67/3667 Ibu 27/1758 Diclo 33/1840	no data
C-105 OA/RA 12 weeks	OA/RA (Documented ≥3 months) requiring NSAID, FC 1-3 Assessment at baseline, 4, 8, 12 weeks Endoscopy at baseline, 12 weeks Double dummy method Washout ≥30 days for diclo QS 5/5; VS 16/16	Cele 2x100mg/day (n=327) Diclo 2x50mg/day (n=330)	Cele 37/327 Diclo 40/330	Cele 11/327 Diclo 7/330	Cele 12/327 Diclo 18/330 GI-related: Cele 7/327 Diclo 14/330	Any AE: Cele 127/327 Diclo 150/330 GI-related: Cele 92/327 Diclo 115/330 Serious: Cele 2/327 Diclo 4/330 Serious GI: Cele 2/327 Diclo 1/330	Dyspepsia: Cele 9/327 Diclo 16/330 Abdom Pain: Cele 43/327 Diclo 62/330 Nausea: Cele 8/327 Diclo 12/330 Diarrhoea: Cele 6/327 Diclo 5/330 Vomiting: Cele 6/327 Diclo 5/330	Gastric ulcer: Cele 0/327 Diclo 2/330 Peptic ulcer: Cele 0/327 Diclo 2/330 Duodenal ulcer: Cele 2/327 Diclo 1/330	Mod/severe abdom pain, nausea, dyspepsia: Cele 20/327 Diclo 30/330	Peripheral oedema: Cele 2/327 Diclo 3/330 Facial oedema: Cele 4/327 Diclo 1/330 Oedema: Cele 0/327 Diclo 3/330 Hypertension: Cele 7/327 Diclo 12/330		Hct ≥5%decrease: Cele 30/327 Diclo 31/330 Hb ≥20g/L decrease: Cele 32/327 Diclo 40/330 Creatinine ≥1.3xULN: Cele 1/327 Diclo 0/330	Cele 18/327 Diclo 20/330

C-106 OA/RA 12 weeks	OA/RA (Documented), requiring NSAID FCC 1-3 Assessment at baseline, 4, 8, 12 weeks Endoscopy at baseline and 12 weeks Double dummy method Washout ≥30 days for diclo QS 5/5; VS 16/16	Cele 2x100mg/day (n=63) Diclo 2x50mg/day (n=61)	Cele 7/63 Diclo 11/61	Cele 1/63 Diclo 4/61	Cele 1/63 Diclo 4/61 GI-related: Cele 0/63 Diclo 3/61	Any: Cele 29/63 Diclo 37/61 GI-related: Cele 9/63 Diclo 17/61 Serious: Cele 2/63 Diclo 1/61 Serious UGI: Cele 0/63 Diclo 0/61	Dyspepsia: None reported Abdom Pain: Cele 6/63 Diclo 10/61 Nausea: Cele 2/63 Diclo 1/61 Diarrhoea: Cele 2/63 Diclo 3/61 Vomiting: None reported	Haemorrhagic gastric ulcer: Cele 0/63 Diclo 1/61	Mod/severe abdom pain, nausea, dyspepsia: Cele 0/63 Diclo 2/61 "Mod/severe GI related": Cele 0/63 Diclo 6/61	Facial oedema: Cele 2/63 Diclo 0/61 Peripheral oedema: Cele 0/63 Diclo 3/61 No reports of hypertension or CHF ??MI	Hct ≥5% decrease: Cele 2/63 Diclo 2/61 Hb ≥20 g/L decrease: Cele 0/63 Diclo 0/61 Creatinine ≥1.3xULN: Cele 0/63 Diclo 0/61	Cele 2/63 Diclo 2/61
C-107 OA/RA 12 weeks	OA/RA (Documented ≥3 months), requiring NSAID, FC 1-3 Assessment at baseline, 4, 8, 12 weeks Endoscopy at baseline, 12 weeks Double dummy method Washout ≥30 days for diclo QS 5/5; VS 16/16	Cele 2x100mg/day (n=44) Diclo 2x50mg/day (n=44)	Cele 6/44 Diclo 9/44	Cele 1/44 Diclo 2/44	Cele 2/44 Diclo 5/44 GI-related: Cele 2/44 Diclo 3/44	Any: Cele 28/44 Diclo 32/44 GI-related: Cele 13/44 Diclo 11/44 Serious: Cele 2/44 Diclo 4/44 Serious UGI: Cele 1/44 Diclo 0/44 Serious CV: Cele 1/44 Diclo 1/44	Dyspepsia: Cele 0/44 Diclo 5/44 Abdom pain: Cele 13/44 Diclo 3/44 Nausea: Cele 2/44 Diclo 1/44 Diarrhoea: Cele 2/44 Diclo 1/44 Vomiting: Cele 4/44 Diclo 1/44		Mod/severe abdom pain, nausea, dyspepsia: Cele 7/44 Diclo 6/44	Facial oedema: Cele 0/44 Diclo 1/44 Hypertension: Cele 1/44 Diclo 1/44 No report of MI or CHF	Week 12 Hct ≥5% decrease: Cele 1/44 Diclo 0/44 Hb ≥20g/L decrease: None Creatinine ≥1.3xULN: None	Cele 7/44 Diclo 13/44

Abdom = abdominal; ACR = American College of Rheumatology; AE = adverse event; BP = blood pressure; Cele = celecoxib; CF = cardiac failure; CHF = chronic heart failure; Clin = clinically; CV = cardiovascular; Diclo = diclofenac; GI = gastrointestinal; GIH = gastrointestinal haemorrhage; GIH = gastrointestinal haemorrhage; Hct = haematocrit; Ibu = ibuprofen; K-L = Kellgren-Lawrence; Loxo = loxoprofen; MI = myocardial infarction; Mod = moderate; Naprox, Nap = naproxen; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; Para = paracetamol; Para = paracetamol; periph = peripheral; Plac = placebo; QS = quality score; Rofe = rofecoxib; sig = significant; Trad = traditional; UGI = upper gastrointestinal; VAS = visual analogue scale; VS = validity score.